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A b s t r a c t  
The purpose of this study is to develop a targeted drug carrier system. Magnetic poly (ē-
caprolactone) (PCL) microspheres were prepared using classical oil-in-water solvent evaporation 
method by loading magnetite nanoparticles and anticancer drug etoposide. The prepared magnetic 
microspheres were smooth, free flowing, individual and homogenous in nature. Fourier transformed 
infrared spectroscopy studies revealed the absence of any potential incompatibility of drug with 
other excipients. DSC studies were conducted to study the state of etoposide in the formulation. 
Further the magnetic microspheres were characterized for entrapment efficiency, drug loading, 
invitro release studies and subjected to particle size analysis and scanning electron microscopy. The 
magnetite nanoparticles were well dispersed in polymer matrix, which are responsible for magnetic 
response. The magnetic property of the prepared microspheres was measured by using vibrating 
sample magnetometer. The amount of magnetite in the formulation was estimated quantitatively by 
atomic absorption spectroscopy which was about 31.5%. The experimental results proved that the 
magnetic microspheres exhibited superparamagnetic behavior and the saturation magnetization was 
7.26 emu/g. The optimized formulations exhibited a narrow size distribution which were below 10 
μm and are evident from SEM analysis. Formulation batches prepared with drug/polymer ratio 1:10 
showed a maximum encapsulation efficiency and the invitro release profile in phosphate buffer (pH 
7.4) solution showed an extended release of etoposide up to 76.25% at the end of 21 day. 
Histopathological studies proved that the etoposide loaded magnetic microspheres were nontoxic 
and safe. 
Keywords: poly (ē-caprolactone), solvent evaporation, superparamagnetic, saturation magnetization 
Introduction 
The rationale behind the development of polymeric controlled 
delivery systems is to make a therapeutic agent do its best when 
administered into the body. These systems are one of the most 
attractive areas in drug delivery and drug targeting [1,2].  Despite 
several advantages offered by controlled drug release, a major 
problem associated with all these systems so far developed is 
uniform biodistribution throughout the body, lack of drug specificity, 
requirement of excess dose to achieve high local concentration, 
non-specific toxicity and adverse side effects. Hence the 
development of drug system that deliver the drug molecules to the 
tumor site, without a concurrent increase in its concentration near 
healthy cells of the tissues, is one of the most active area of 
investigation in cancer research [3].  
Among all the existing targeting drug delivery systems, a promising 
one will be the system associated with external or feedback control 
such as magnetic control [4,5]. The technique is based on the 
principle that the drug is encapsulated with magnetite 
nanoparticles, covered by a polymer shell. The existence of 
magnetic particles in magnetic microspheres will make them 
specifically transported to the target site under the influence of 
external magnetic field. On reaching the target organ or tissue, the 
magnetic vehicles release the drug in a temporal manner. The 
magnetically targeted therapy can be effective to lower the toxic 
effects and to enhance the therapeutic effect of drug because of 
the characteristics of driven magnetic accuracy, targeting and high 
drug capacity[6-8]. 
Magnetic particles are usually made of magnetite (Fe3O4), 
maghemite (γ ă Fe2O3), cobalt ferrite (Fe2CoO4), chromium dioxide 
(CrO2) etc. Among them magnetite is extensively used, properly 
characterized in various aspects, whose toxicity has been 
demonstrated to be low and well tolerated in human body[9,10]. 
Biocompatible and biodegradable polymers have been widely used 
for the controlled drug release [11,12]. The polymeric shell can 
consist of different kinds of polymers such as poly (ē-caprolactone) 
(PCL), polylactides (PLA) and polyglycolide (PGA) are of great 
interest in design of carrier based drug delivery. The 
biocompatibility, biodegradability and greater permeability of PCL 
make it suitable for controlled drug delivery and wide use in 
medical applications. Its compatibility with wide range of drugs 
enables uniform drug distribution in the formulation matrix and its 
long term degradation facilitates drug release up to several 
months[13,14]. The investigation on PCL formulations revealed 
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that the mechanism of drug release is often dominated by diffusion 
from microsphere matrix, by which the lipophilic drug release can 
be controlled in vivo from PCL formulations for much longer 
duration [15,16].   
Etoposide is a semisynthetic derivative of podophyllotoxin that 
exhibits superior antitumor activity. Etoposide inhibits DNA 
topoisomerase II, thereby inhibiting DNA synthesis at the premiotic 
stage of cell division. Etoposide is cell cycle dependent and phase 
specific, affecting mainly the S and G2 phases of cell division and 
cause cell death. Etoposide is considered as major standard 
cytotoxic drug for small lung cancer [17]. The chemotherapy 
regimens that utilize etoposide are more effective when the drug is 
given over an extended period of time [18, 19]. 
The present work is aimed to develop etoposide loaded PCL 
magnetic microspheres that ensure the delivery of concentrated 
dose of etoposide directly into the tumor, which will eliminate the 
need for patient to consume large quantities of the drug. The 
developed magnetic microspheres were characterized for 
morphology, size distribution, encapsulation efficiency, magnetic 
property and in vitro release. 
Materials and Methods 
Poly (ē-caprolactone) M.Wt.45000, polyvinyl alcohol (M.wt 15000-
20,000), Magnetite (iron II, III oxide) nanopowders < 50nm was 
purchased from sigma ă Aldrich chemical co. (USA). Etoposide 
was a gift sample obtained from Cedilla India ltd., Mumbai. 
Potassium dihydrogen orthophosphate and sodium hydroxide were 
purchased from SD fine chemicals ltd., Mumbai. All solvents 
(dichloromethane, methanol) used in the preparation were of 
analytical grade and purchased from Qualigens fine chemicals, 
Mumbai. 
Preparation of drug loaded PCL magnetite 
microspheres by O/W emulsion method. 
The magnetic loaded PCL microspheres containing etoposide were 
prepared by O/W emulsion- solvent evaporation technique using 
polyvinyl alcohol as the external aqueous phase. The method was 
similar to the procedure previously reported for the development of 
etoposide loaded controlled release PCL microspheres [20]. 
Briefly, the required amount of PCL, magnetite and drug were 
dissolved in 10 ml of dichloromethane. The organic phase was 
added slowly to the 40 ml of aqueous phase containing 1% PVA as 
stabilizer. The mixture was emulsified with the help of a high speed 
homogenizer [Turrax T25, IKA] at 5000 rpm. The formed O/W 
emulsion was stirred under a magnetic stirrer for 3 h at 1000 rpm 
under room temperature to make free of organic phase. The 
magnetic microspheres so formed were collected with the help of 
placing a magnet of 8000G strength at the bottom of the beaker, 
washed thrice with distilled water, filtered and dried at 45oC. All 
formulations were transferred to glass vial and stored in a 
desicator. 
Morphology and particle size 
The studies on morphology of samples were carried out using 
scanning electron microscopy (SEM, JOEL-JFC 5300). Magnetic 
microspheres were dispersed in distilled water, dripped in 
aluminium foil and evaporated. The dried magnetic microspheres 
were mounted on a copper stub and coated with gold palladium 
under vacuum using an ion sputter coater (JEOL JFC 1100E) for 
observation under scanning electron microscope. The formulated 
magnetic microspheres were characterized by optical microscopy 
for particle size and size distribution. The eye piece micrometer 
was calibrated with the help of a stage micrometer. The average 
particle size was determined using EdmundsonÊs equation Dmean = 
Ʃnd/Ʃn, where n is the number of microspheres counted and d is 
the mean size range. 
Determination of drug loading and encapsulation 
efficiency 
The formulated magnetic microspheres were estimated for their 
loading and encapsulation efficiency by using the equations 1 and 
2 respectively. 
 
 Drug loading (%) = mc/mt x 100     ---------- 1 
 Encapsulation efficiency (%) = mc/ mθ x 100    ---------- 2 
 
where mc is mass of etoposide in magnetic microspheres, mθ is the 
total mass of the drug and mt is the total mass of magnetic 
microspheres. 
An accurately weighed amount of drug loaded magnetic 
microspheres (100 mg) were dissolved in 10 ml of 
dichloromethane: methanol mixture in screw cap (Teflon tube). The 
tubes were shaken vigorously for 1 min. The contents were filtered 
by using a 0.1μ millipore filter assembly and suitably diluted with 
respective solvent system. The UV absorbance of the solution was 
measured using the UV/ Vis spectrophotometer (Perkin Elmer- 
LAMBDA 25) at 283 nm and the concentration was calculated 
according to the standard regression. 
Fourier Transformed Infrared Spectroscopy (FTIR) 
analysis 
The FTIR spectroscopy was used to characterize the drug, 
polymer, magnetite and the formulated magnetic microspheres. 
The samples were recorded on a Perkin Elmer-(Spectrum RX) 
using the conventional KBr pellet method. All samples were 
scanned in the IR range from 400- 5000cm-1at 25oC.  
State of etoposide in magnetic microspheres 
Differential scanning calorimetry was used to determine the 
thermal behavior of etoposide, polycaprolactone, magnetite and 
magnetic microsphere formulations. Samples were scanned for the 
melting temperatures in nitrogen atmosphere by Perkin Elmer 
DSC-7. Samples were placed in hermetically sealed aluminium 
pans and heated at a scan speed of 10 oC per min over a 
temperature range of 30- 500o C at a chart speed of 10 ml/min. 
The heat of fusion was calibrated with indium.  
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Determination of magnetic property 
The magnetic properties of Fe3O4/PCL microparticles were 
measured by using a Vibrating Sample Magnetometer (VSM) [DMS 
1600]. The samples in the form of powder were placed in Teflon 
sample holder. The magnetic properties were then determined by 
an increasing magnetic field over the sample. The measurements 
were carried out in the field range of μ 1 T at room temperature. 
Determination of magnetic content  
The content of magnetite in formulations was estimated 
quantitatively by atomic absorption spectroscopy (AAS) [SL 173, 
Elico]. A preweighed (100 mg) amount of magnetic microspheres 
was digested with 5ml of HCl and 5ml of HNO3 in CEM microwave 
digester using MARSX press at 800psi and 200oC. The digested 
solution was made up to 500ml using de-ionized water and was 
thoroughly filtered using whatman 40 filter paper. The clear solution 
was assayed for iron by AAS at 248 nm. The weight percentage of 
iron content in the formulation can be calculated from the equation 
 
          ppm (mg/L) X Volume in mL X dilution 
factor X 10-4 
   Wt % =      --------------------------------------------------------------------- 
                       Weight of sample in grams  
 
where, ppm (mg/L) is the result obtained from the instrument, 
Volume in ml- is the volume required for digestion, weight of 
sample in gm- 0.100gm for all the samples. 
In vitro drug release studies 
The in vitro drug release studies for formulated magnetic 
microspheres were carried out in phosphate buffer (pH 7.4) at 37.5 
μ 0-5o C. Dried samples of drug loaded polycaprolactone magnetic 
microspheres (35 mg) were put into a dialysis bag immersed in 50 
ml of phosphate buffer (pH 7.4) in a conical flask. [21, 22] The flask 
was placed in an orbital shaker incubator  [C 24, Remi] and rotated 
at 50 rpm. At predetermined time intervals the flasks were taken 
out of the shaker, 5 ml aliquots of the medium were withdrawn and 
the same volume of fresh medium was added to the bulk to 
maintain the sink condition. The amount of drug released in media 
was analyzed by using UV- Visible spectrophotometer [Lambda 25, 
Perkin Elmer]. 
Histological studies 
Presence of excipients in the formulation may sometimes produce 
toxicity which may be immediate or delayed toxicity. In order to 
ascertain the safety, the formulations were administered to group 
of Wistar Albino rats and the vital organs like liver, kidney, heart, 
brain and lungs were removed. The histopathological evaluation of 
the tissues with etoposide loaded PCL magnetic microspheres 
administered rats were fixed in 10% formalin, routinely processed 
and embedded in paraffin. Sections were cut on glass slides and 
stained with hematoxyllin and eosin.[23] The sections were 
examined under a light microscope to detect any damage occurred 
to the tissue and were compared with similar sections of tissues 
isolated from untreated rats. Studies were performed under OECD 
guidelines no 423.  
Results and Discusssion 
Characterization of magnetic microspheres 
The prepared polycaprolactone magnetic microspheres loaded with 
etoposide were characterized for their morphology and size 
distribution. Figure 1 shows the morphology of magnetic 
microspheres obtained by scanning electron microscopy. The 
microspheres obtained are free flowing. As evidenced from the 
figure the microspheres are smooth and spherical in shape.  
 
 
 Figure 1: SEM images of polycaprolactone magnetic microspheres 
 The 
conc
is va
and 
magn
ratio 
distri
9.08μ
incre
highe
of co
 
For
 
       
magnetic mic
entrations of PC
ried in formulati
size distribution
etic microsphe
was shown in t
bution of prep
m. Increase i
ase in mean p
r concentration
llisions, resultin
Table 1: Comp
mulation code 
F 1 
F 2 
F 3 
F 4 
F 5 
F 6 
F 7 
F 8 
F 9 
F 10 
F 11 
F 12 
  Figure 2
rospheres we
L as shown in t
ons to investiga
. The mean pa
res of etoposi
able 1 and figur
ared microsph
n the concentr
article size. It 
 of polymer ma
g in fusion of se
osition, mean p
Drug/polymer
ratio
1:1:
1:1:
1:1:
1:1:
1:5:
1:5:
1:5:
1:5:
1:10
1:10
1:10
1:10
: Particle size d
S
re formulated 
able 1. The amo
te the influence
rticle size of po
de with differen
e 2, 3 and 4. T
eres ranged fr
ation of polym
could be sugg
y lead to increa
mi particles and
article size, drug
/magnetite  
 
1 
2 
3 
4 
1 
2 
3 
4 
:1 
:2 
:3 
:4 
istribution of eto
undar et al. 
with different 
unt of polymer 
 of particle size 
lycaprolactone 
t dug/polymer 
he particle size 
om 4.8μm to 
er resulted in 
ested that the 
sed frequency 
 finally produce 
 loading, encap
Mean Particle S
(μm) 
4.80
5.10
5.27
4.68
6.05
6.19
6.40
6.80
9.08
8.22
7.88
8.42
poside loaded p
International 
 
bigger
Polyvi
in the
were 
solven
viscos
evapo
coales
emuls
other 
sulation efficien
ize Drug
Loading
4.00
4.67
3.92
3.60
5.84
5.10
4.80
4.10
6.12
5.70
5.21
4.84
olycaprolactone
Journal of Dr
 particles there
nyl alcohol at a 
 formulation. T
common occu
t evaporation 
ity and gradual 
ration [25].  Th
cence and agg
ion droplets, th
and its consequ
cy and magnetit
 
 (%) 
Enca
 magnetic  micr
ug Delivery 6 
P
by increasing th
concentration of
he coalescenc
rrence in prep
process were 
decrease in the
e presence of 
lomeration by fo
us preventing t
ences. 
e concentration
psulation efficie
(%) 
48.2 
47.4 
44.3 
40.2 
61.4 
59.5 
53.8 
53.0 
69.4 
69.0 
64.0 
62.3 
ospheres with  d
(1) 24-35 [2
AGE | 27 |
e size of micro
 1% was used a
e and agglome
aration of mic
probably due to
 volume as a re
polyvinyl alcoho
rming a thin fil
heir approach 
 of prepared mic
ncy  M
Conce
rug/polymer rat
014] 
spheres [24]. 
s a surfactant 
ration, which 
rospheres by 
 increase in 
sult of solvent 
l reduces the 
m around the 
towards each 
rospheres 
agnetite 
ntration (%) 
13.6
14.7
13.5
15.2
14.3
17.7
19.3
22.7
17.7
21.9
31.5
30.8
 
io 1:1 
   
 
  
 
Effic
The 
micro
that 
dichl
enca
table
Figure 3: P
Figure 4: P
iency of enca
amount of drug
spheres was d
could be reco
oromethane: 
psulation of all 
 1. An increase
article size distr
article size distr
psulation    
 encapsulated 
etermined by c
vered after dis
methanol mix
formulations we
 in concentrati
S
ibution of etopo
ibution of etopo
in each of polym
alculating the a
solving the m
ture. The 
re investigated 
on of polymer 
undar et al. 
side loaded poly
side loaded poly
eric magnetic 
mount of drug 
icrospheres in 
efficiency of 
and reported in 
resulted in the 
International 
 
caprolactone m
caprolactone m
increa
Benoit
increa
migrat
 
 
Journal of Dr
agnetic microsp
agnetic microsp
sed entrapment
 [24]. The enh
se in viscosity 
ion of drug to th
ug Delivery 6 
P
heres with drug
heres with drug
 efficiency. This
ancement in po
of organic pha
e external wate
(1) 24-35 [2
AGE | 28 |
/polymer ratio 1
/polymer ratio 1
 effect was also
lymer concentr
se which in tu
r phase. 
014] 
:5 
:10 
 observed by 
ation leads to 
rn restrict the 
 Fou
Figur
micro
spec
micro
very 
etopo
cm-1 
chara
at 16
ă 16
inten
 
 F
 
rier Transform
e 5 shows the
spheres prepa
tra of etoposide
spheres were 
important for 
side (Figure 5 
which is char
cteristic intense
14 cm-1. The C=
10 cm-1 region
sity compared 
igure 5: Infra re
ed Infrared S
 FTIR spectra 
red by o/w e
, PCL, Fe3O4 n
analyzed. The f
diverse applica
A) exhibits a br
acteristic of p
 doublet of ethe
C stretching of 
. This band i
with the C=C 
d spectrum of  A
S
pectroscopy
of magnetic po
mulsion metho
anoparticles an
unctional group
tions. The FT
oad band betw
henolic  - OH 
r showed C=C 
vinyl ethers occ
s characterized
stretching band
) pure drug eto
undar et al. 
 
lycaprolactone 
d. The FT-IR 
d the magnetic 
s of PCL were 
IR spectra of 
een 3400-3700 
group and a 
stretched band 
urs in the 1660 
 by its higher 
 in alkene. A 
poside  B) Polyc
magneti
International 
 
charac
presen
strong
carbon
nanop
400 cm
conten
cm-1[2
D) the
existe
chemi
micros
in the 
aprolactone C) 
c microsphere fo
 
 
Journal of Dr
teristic broad a
ce of hydroge
 carbonyl stretc
yl bond that 
articles (Figure
-1) due to the i
t the pattern o
6].  In the IR s
 characteristic
d in the same w
cal interaction 
pheres and the
polymer matrix.
Fe3O4magnetic
rmulation. 
ug Delivery 6 
P
bsorption band
n bonded OH 
hing band at 1
come from P
5 C) exhibit at 
ron oxide struct
f magnetite (Fe
pectrum of mag
 absorption ba
ave number. T
between polym
 presence of dr
  nanoparticles 
(1) 24-35 [2
AGE | 29 |
 at 3412 cm-1
group. Figure 
724 cm-1 revea
CL. The spect
low frequency 
ure. Depending 
3O4) spectrum 
netic microsphe
nds of etopos
his indicates th
er and drug 
ug as a molecu
and  D) Etoposi
014] 
is due to the 
5 B shows a 
led the ester 
ra of Fe3O4 
region (600 ă 
on Fe (II) (III) 
shows at 570 
res (Figure 5 
ide and PCL 
e absence of 
in magnetic 
lar dispersion 
 
de loaded 
 Diffe
The 
quan
DSC
loade
6 A -
were
loade
that 
 
Figu
rential Scann
DSC method of
tity and physico
 thermograms fo
d PCL magneti
D). The glass tr
 present at 28
d magnetic mic
of PCL polymer
re 6: DSC Ther
ing Calorime
 analysis is quit
 chemical status
r free drug, PC
c microsphere f
ansition temper
3.7oC and 77.7
rosphere exhibi
 and did not sh
mograms of form
S
try 
e informative ab
 of the drug in t
L, polymer, mag
ormulations wer
ature of pure dru
oC. The therm
ts similar shape
ow any detecta
ulated magnet
undar et al. 
out the quality, 
he formulation. 
netite and drug 
e given (Figure
g and polymer 
ogram of drug 
 and position to 
ble endotherm 
ic microspheres
microsp
International 
 
corres
300oC
the fo
or mo
so as 
etopos
interm
formu
: A) Pure drug; 
here formulatio
 
Journal of Dr
ponding to melt
. However, the 
rmulation indica
lecular disperse
reach improved
ide in magne
olecular forces
lation of microsp
B) PCL polymer
n 
ug Delivery 6 
P
ing temperature
absence of dete
tes the presenc
d state which pr
 biological acti
tic microsphere
 between etop
heres. 
; C) Magnetic na
(1) 24-35 [2
AGE | 30 |
s of free drug b
ctable melting p
e of drug in am
oves to enhance
vity. The amorp
 contributes t
oside and PC
 
noparticles and
014] 
etween 200 - 
eak of drug in 
orphous state 
 the solubility 
hous state of 
o the strong 
L during the 
 D) Magnetic 
Sundar et al. International Journal of Drug Delivery 6 (1) 24-35 [2014] 
 
PAGE | 31 |
 
 
Magnetic property of magnetic microspheres       
The superparamagnetic property of polymer magnetic microsphere 
is critical for their application in biomedical and bioengineering 
fields which prevents polymer magnetic microspheres from 
aggregation and enables them to redisperse rapidly when the 
magnetic field is removed [6]. The magnetization curves of the 
naked Fe3O4 particles (figure 7(a)) and Fe3O4 drug loaded 
polycaprolactone magnetic microspheres (figure 7(b)) recorded 
with VSM are illustrated in figure 7. As shown in the figure the 
magnetization of the samples would approach the saturation 
values when the applied magnetic field increases to 10,000 Oe. 
The saturation magnetization (Ĕs) of magnetite was found to be 
24.82 emu/g and that of microsphere formulation was found to be 
7.26 emu/g. The saturation magnetization of magnetic 
microspheres was much less than that of bulk magnetite as 
reported in the literature for this material [27].  Figure 7(a) and Fig 
7(b) represents a typical characteristic of superparamagnetic 
material with no detected remainance or coacervity at room 
temperature indicated that the single domain magnetic Fe3O4 
nanoparticles remained in the prepared magnetic microspheres. 
 
 
Figure 7: Magnetization curves obtained by vibrating sample magnetometer (VSM) at room temperature. (a) Fe3O4 nanoparticles (b) Fe3O4 / 
PCL magnetic microspheres. 
 
Content of magnetic particles 
The study includes the incorporation of Fe3O4 nanoparticles along 
with drug and encapsulated with polycaprolactone. The presence 
of magnetic particles can carry the drug to a specific target site 
quickly under the external magnetic field. The concentration of 
magnetite included within the polymeric carriers was estimated in 
terms of weight percentage by atomic absorption spectroscopy. 
The amount of magnetite in the polymeric microspheres increases 
with the increase in the polymer concentration which was illustrated 
in table 1. Microspheres fabricated with 1:10 drug/polymer ratio 
could accommodate highest amount of magnetite. On the other 
hand, the magnetite and drug compete with each other to dwell into 
the matrix space of the polymeric droplets during its formation. 
Accordingly the ability of the microspheres to entrap the drug 
decreases with increase in magnetite concentration.  
The average amount of magnetite within the spheres was found to 
be 19.4%w/w.  This concentration of nanoparticulate magnetite 
within the polymeric vehicles could be sufficient to direct the 
microspheres to reach their destination target site. Such a 
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Histopathological analysis of various organs like brain, heart, liver, 
lungs and kidney of animals treated with encapsulated etoposide 
was illustrated in figure 11a-11e.The vital organs were assessed 
for toxic effects of etoposide loaded polycaprolactone magnetic 
microspheres. The cross section of brain, heart and liver of treated 
animals were examined for cell necrosis, cellular hoemostasis and 
inflammation on hepatic cells. None of these signs was detected, 
revealing there was no significant toxicity produced by the 
formulations (Figure 11a, 11b and 11c). Enlarged airway spaces 
and necrosis of alveoli on cross examination of the cells of the 
lungs were found to be absent, hence signifying no toxic effects 
(Figure 11d). A toxicity produced kidney is identified by reversible 
lesions such as interstitial fibrosis. The cross sections of the 
kidneys showed no such effects, thus signifying no toxic effects of 
the drug (Figure 11e). Hence it was concluded from the 
microphotographs that no histological alterations were observed in 
various organs of animals treated with encapsulated etoposide. 
Conclusion 
The poly (ē- caprolactone) microspheres containing magnetite and 
anticancer drug were successfully formulated by O/W emulsion 
solvent evaporation method with maximum drug encapsulation and 
desired release profile. The method adopted favored the formation 
of smooth, spherical shaped microspheres with optimal particle 
size. The formulated magnetic microspheres were magnetically 
responsive and this synthetic approach is applicable for producing 
magnetic polymer microspheres with high magnetite contents. The 
possession of sufficient paramagnetic property was confirmed by 
VSM. The histopathological studies proved that the etoposide 
loaded magnetic microspheres was nontoxic and safe. The results 
suggested that the magnetic PCL magnetic microspheres may 
have potential as a highly versatile carrier for targeted delivery 
approach.    
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